Rosuvastatin /day

ApprovedSmall molecule

IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Rosuvastatin /day is one of 93 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Breast CancerActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Rosuvastatin /day

IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Tecentriq

Roche

Preclinical

36 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Acupan

YYonsei University

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Post-ApprovalNot yet recruiting

Breast Cancer

NCT07254221

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients

Not yet recruiting·SShiraz University of Medical Sciences·Phase 4·NCT07254221·400 enrolled

HIV infection1 trial

Rosuvastatin to Decrease Residual Immune Activation in HIV Infection

Unknown status·IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·Phase 2·NCT01874743·40 enrolled

Acute Coronary Syndrome1 trial

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

Recruiting·KKing Edward Medical University·Phase 4·NCT06765265·152 enrolled

Endothelial Function1 trial

Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function

Completed·OOdense University Hospital·Phase 4·NCT01223625·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Rosuvastatin /day. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosuvastatin /day compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosuvastatin /day. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Rosuvastatin /day

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Breast Cancer1 trial

HIV infection1 trial

Acute Coronary Syndrome1 trial

Endothelial Function1 trial

References

Drug Info

Quick Facts

Related News